Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2018 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update

– Key focus on advancing the development of MAT9001, a proprietary, potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only omega-3...
October 18, 2018 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001 Providing Protection Through 2033

BEDMINSTER, N.J., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Patent and Trademark...
October 16, 2018 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the 8th Annual Partnership Opportunities in Drug Delivery Conference

BEDMINSTER, N.J., Oct. 16, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that Raphael Mannino, Ph.D., Chief...
October 15, 2018 08:01 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team

- Dr. Matkovits is an industry leader with 20+ years of proven global drug development success bringing 4 approved medicines to several global markets - - Frank Calamusa, CSCP, an established biotech...
September 25, 2018 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the MicroCap Conference

BEDMINSTER, N.J., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular...
September 06, 2018 08:01 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Appointment of Industry Leader Patrick G. LePore to Board of Directors

BEDMINSTER, N.J., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery...
September 05, 2018 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

BEDMINSTER, N.J., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular...
August 16, 2018 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the U.S. FDA Development of Non-Traditional Therapies for Bacterial Infections Workshop

BEDMINSTER, N.J., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on enabling targeted intracellular delivery...
August 10, 2018 08:15 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports Second Quarter 2018 Financial Results and Provides Corporate Update

– Management intently focused on advancing proprietary and highly differentiated lipid nano-crystal platform delivery technology – – Multiple discussions with strategic partners remain ongoing – –...
July 09, 2018 09:15 ET | Source: Matinas BioPharma Holdings, Inc.

NIH and Matinas BioPharma Announce Research Collaboration to Identify Novel HIV Therapy Utilizing LNC Platform Delivery Technology

- Development program to focus on combination of antisense oligonucleotides with Matinas’ Proprietary LNC Delivery Technology - BEDMINSTER, N.J. and WASHINGTON, July 09, 2018 (GLOBE NEWSWIRE)...